Blood Pressure Assessment in Atrial Fibrillation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01088269|
Recruitment Status : Recruiting
First Posted : March 17, 2010
Last Update Posted : September 14, 2017
This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:
- clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
- 24-hour ambulatory blood pressure monitoring
- determination of various serum markers and cardiac ultrasound.
- evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Hypertensive patients in AF
- Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF) [ Time Frame: Baseline ]
- Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.
- Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.
- Evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088269
|Contact: George S Stergiou, MDfirstname.lastname@example.org|
|Hypertension Center, Third Internal Medicine Dpt, University of Athens||Recruiting|
|Contact: George S. Stergiou 00302107763117 email@example.com|
|Contact: George S. Stergiou, Professor 00302017763117 firstname.lastname@example.org|
|Sub-Investigator: Antonios Th. Destounis, Phd candidate|
|Study Chair:||George S Stergiou, MD||Hypertension Center,Third Department of Medicine,University of Athens,Greece|